drugset / Trial / NCT00717561

A Study to Assess the Efficacy and Safety of IV/PO Moxifloxacin in Subjects With Community-acquired Pneumonia

NCT00717561

Phase 3 Completed 60 enrolled Bayer
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess if a therapy with oral and intravenous moxifloxacin is as effective as a therapy with intravenous ceftriaxone + intravenous azithromycin followed by oral amoxicilline/clavulanate and oral clarithromycin in the treatment of community-acquired pneumonia.

Timeline

Start
2008-02
Primary completion
2009-05
Completion
2009-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Amoxicilline/clavulanate Unknown 1000 mg Oral
Comparator Azithromycin Small molecule 500 mg Intravenous
Comparator Ceftriaxone Other / unclassified 2 g Intravenous
Comparator Clarithromycin Small molecule 500 mg Oral
Subject Moxifloxacin Small molecule 400 mg Intravenous

Indications